Likewise, the positivity rates of IGF2BP3 in ER negative, PR negative, and breast cancer patients with a higher Ki-67 index (≥14%) were 26.0% (34/131), 20.4% (33/162), and 20.1% (34/169) respectively, all significantly higher than those in ER positive (0.0%, 0/168), PR positive (0.7%, 1/137), and low Ki-67 index (<14%) (0.0%, 0/125) patients (all P<0.001). Here, MKI67 is linked to breast carcinoma.